SIMCERE PHARMA2096.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 16, 2026, SIMCERE PHARMA (2096.HK) trades at a P/E of 15.80x, P/B of 2.60x, P/S of 2.84x, and a dividend yield of 1.88%.
Longitudinal percentile comparison: P/E sits at the 23rd percentile over the trailing 10Y window (vs. 11th percentile over 3Y); P/B sits at the 34th percentile over the trailing 10Y window (vs. 51st percentile over 3Y); P/S sits at the 32nd percentile over the trailing 10Y window (vs. 51st percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 58th percentile within its industry and the 66th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 3.29%, ranking at the 70th percentile over the trailing 20Y window.
The P/E and P/B long-window percentiles differ by only 10.6 points, pointing to a consistent valuation read across both metrics. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Breaking down the total shareholder yield: 1.88% comes from cash dividends, with an implied ~1.41% from buybacks — a fairly balanced mix of both channels. SIMCERE PHARMA operates in the Pharmaceutical Chemistry sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 2096 · SEHK: 2096 · 2096
Want the full picture on whether SIMCERE PHARMA (2096.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 15.80 | ||||||
| P/B (MRQ) | 2.60 | ||||||
| P/S (TTM) | 2.84 | ||||||
| Dividend Yield | 1.88% | ||||||
| Buyback + Div Yield | 3.29% |